Search Results - "FITCHETT, David H"

Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials by Verma, Subodh, Dr, Farkouh, Michael E, MD, Yanagawa, Bobby, MD, Fitchett, David H, MD, Ahsan, Muhammad R, MD, Ruel, Marc, Prof, Sud, Sachin, MD, Gupta, Milan, MD, Singh, Shantanu, Gupta, Nandini, MD, Cheema, Asim N, MD, Leiter, Lawrence A, Prof, Fedak, Paul W M, MD, Teoh, Hwee, PhD, Latter, David A, MD, Fuster, Valentin, Prof, Friedrich, Jan O, Dr

“…Summary Background The choice between coronary artery bypass surgery (CABG) and percutaneous coronary intervention (PCI) for revascularisation in patients with…”
Get full text

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial by Ferreira, João Pedro, Kraus, Bettina Johanna, Zwiener, Isabella, Lauer, Sabine, Zinman, Bernard, Fitchett, David H, Koitka-Weber, Audrey, George, Jyothis T, Ofstad, Anne Pernille, Wanner, Christoph, Zannad, Faiez

“…Background Cardio/kidney composite end points are clinically relevant but rarely analyzed in cardiovascular trials. This post hoc analysis of the EMPA-REG…”
Get full text

Optimal medical therapy at discharge in patients with acute coronary syndromes: Temporal changes, characteristics, and 1-year outcome by Yan, Andrew T., MD, Yan, Raymond T., MD, Tan, Mary, BSc, Huynh, Thao, MD, Soghrati, Kamyar, MD, Brunner, Lawrence J., PhD, DeYoung, Paul, MD, Fitchett, David H., MD, Langer, Anatoly, MD, MSc, Goodman, Shaun G., MD, MSc

“…Background There are limited data on the recent trend in the use of optimal evidence-based medical therapies after acute coronary syndromes (ACSs). We sought…”
Get full text

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications by Heerspink, Hiddo J.L, Perkins, Bruce A, Fitchett, David H, Husain, Mansoor, Cherney, David Z I

“…Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are now widely approved antihyperglycemic…”
Get full text

Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome by Fitchett, David H., Leiter, Lawrence A., Lin, Peter, Pickering, Jennifer, Welsh, Robert, Stone, James, Gregoire, Jean, McFarlane, Philip, Langer, Anatoly, Gupta, Anil, Goodman, Shaun G.

“…A recent acute coronary syndrome provides an opportunity to optimise secondary prevention strategies to reduce the risk of future cardiovascular events. This…”
Get full text

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial by Verma, Subodh, Mazer, C David, Yan, Andrew T, Mason, Tamique, Garg, Vinay, Teoh, Hwee, Zuo, Fei, Quan, Adrian, Farkouh, Michael E, Fitchett, David H, Goodman, Shaun G, Goldenberg, Ronald M, Al-Omran, Mohammed, Gilbert, Richard E, Bhatt, Deepak L, Leiter, Lawrence A, Jüni, Peter, Zinman, Bernard, Connelly, Kim A

“…BACKGROUND:SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular events in type 2 diabetes mellitus but whether they promote direct cardiac…”
Get full text

Influence of Age on Use of Cardiac Catheterization and Associated Outcomes in Patients With Non-ST-Elevation Acute Coronary Syndromes by Bagnall, Alan J., MB, ChB, PhD, Goodman, Shaun G., MD, MSc, Fox, Keith A.A., MB, ChB, Yan, Raymond T., MD, MASc, Gore, Joel M., MD, Cheema, Asim N., MD, PhD, Huynh, Thao, MD, Chauret, Denis, MD, Fitchett, David H., MD, Langer, Anatoly, MD, MSc, Yan, Andrew T., MD

“…Randomized controlled trials support the use of an early invasive strategy in high-risk patients with non-ST-segment elevation (NSTE) acute coronary syndromes…”
Get full text

Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes by Fitchett, David H., Udell, Jacob A., Inzucchi, Silvio E.

“…Diabetes is a major risk factor for heart failure (HF). Patients with diabetes have a high incidence of both clinical HF and subclinical LV dysfunction…”
Get full text

Relation Between Obesity and the Attainment of Optimal Blood Pressure and Lipid Targets in High Vascular Risk Outpatients by Bhan, Vineet, MD, Yan, Raymond T., MD, Leiter, Lawrence A., MD, Fitchett, David H., MD, Langer, Anatoly, MD, MSc, Lonn, Eva, MD, Tan, Mary, BSc, Silagy, Stewart, MD, Goodman, Shaun G., MD, MSc, Yan, Andrew T., MD

“…Obesity is associated with hypertension, dyslipidemia, and diabetes, but it is also an independent cardiovascular risk factor. We sought to evaluate the…”
Get full text

Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada by Braga, Manoela F.B., MD, Casanova, Amparo, MD PhD, Teoh, Hwee, PhD, Dawson, Keith G., MD PhD, Gerstein, Hertzel C., MD MSc, Fitchett, David H., MD, Harris, Stewart B., MD MPH, Honos, George, MD, McFarlane, Philip A., MD PhD, Steele, Andrew, MD, Ur, Ehud, MB, Yale, Jean-François, MD, Langer, Anatoly, MD MSc, Goodman, Shaun G., MD MSc, Leiter, Lawrence A., MD

“…Objectives To evaluate vascular protection treatment patterns and attainment of the 2003 Canadian Diabetes Association's recommended targets in ambulatory…”
Get full text

Resting heart rate: A modifiable prognostic indicator of cardiovascular risk and outcomes? by Malcolm Arnold, J., MD FRCPC, Fitchett, David H., MD FRCPC, Howlett, Jonathan G., MD FRCPC, Lonn, Eva M., MD FRCPC, Tardif, Jean-Claude, MD FRCPC

“…A growing body of evidence from clinical trials and epidemiological studies has identified elevated resting heart rate as a predictor of clinical events. Proof…”
Get full text

Acute Coronary Syndromes: A Canadian Perspective by Fitchett, David H., MD

Get full text

Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation Myocardial Infarction by Fitchett, David H., MD, Theroux, Pierre, MD, Brophy, James M., MD, PhD, Cantor, Warren J., MD, Cox, Jafna L., MD, Gupta, Milan, MD, Kertland, Heather, PharmD, Mehta, Shamir R., MD, MSc, Welsh, Robert C., MD, Goodman, Shaun G., MD, MSc

“…Abstract Acute ST-segment elevation myocardial infarction (STEMI) accounts for approximately 30% of all acute coronary syndromes (ACS). The high early…”
Get full text

Risk Stratification and Selection for Statin Therapy: Going Beyond Framingham by Fitchett, David H., MD, FRCPC, Mancini, G.B. John, MD, FRCPC, Gregoire, Jean, MD, FRCPC, Anderson, Todd, MD, FRCPC, McPherson, Ruth, MD, PhD, FRCPC

“…Abstract Decisions for statin therapy in the primary prevention of atherosclerotic cardiovascular disease are generally made using the 10-year Framingham Risk…”
Get full text

Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST–Segment Elevation ACS by Fitchett, David H., MD, Theroux, Pierre, MD, Brophy, James M., MD, PhD, Cantor, Warren J., MD, Cox, Jafna L., MD, Gupta, Milan, MD, Kertland, Heather, PharmD, Mehta, Shamir R., MD, MSc, Welsh, Robert C., MD, Goodman, Shaun G., MD, MSc

“…Abstract Despite the reduction of coronary heart disease mortality over the past 40 years, hospital admissions for acute coronary syndromes (ACS) continue to…”
Get full text

Identification and Management of Patients at Elevated Cardiometabolic Risk in Canadian Primary Care: How Well Are We Doing? by Teoh, Hwee, PhD, Després, Jean-Pierre, PhD, Dufour, Robert, MD, MSc, Fitchett, David H., MD, Goldin, Lianne, CCMEP, Goodman, Shaun G., MD, MSc, Harris, Stewart B., MD, MPH, Langer, Anatoly, MD, MSc, Lau, David C.W., MD, PhD, Lonn, Eva M., MD, MSc, John Mancini, G.B., MD, McFarlane, Philip A., MD, PhD, Poirier, Paul, MD, PhD, Rabasa-Lhoret, Rémi, MD, PhD, Tan, Mary K., MSc, Leiter, Lawrence A., MD

“…Abstract Background We evaluated the risk assessment and management patterns employed by primary care physicians in patients at elevated cardiometabolic risk…”
Get full text

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial by Inzucchi, Silvio E, Khunti, Kamlesh, Fitchett, David H, Wanner, Christoph, Mattheus, Michaela, George, Jyothis T, Ofstad, Anne Pernille, Zinman, Bernard

“…Abstract Context Control of multiple cardiovascular (CV) risk factors reduces CV events in individuals with type 2 diabetes. Objective To investigate this…”
Get full text

Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice by Fitchett, David H

“…In patients with type 2 diabetes (T2D), the excretion of glucose by the kidney with sodium-glucose cotransporter 2 (SGLT2) inhibitors lowers glycosylated…”
Get full text

Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial by Vaduganathan, Muthiah, Inzucchi, Silvio E., Sattar, Naveed, Fitchett, David H., Ofstad, Anne Pernille, Brueckmann, Martina, George, Jyothis T., Verma, Subodh, Mattheus, Michaela, Wanner, Christoph, Zinman, Bernard, Butler, Javed

“…Aim To evaluate the effects of empagliflozin versus placebo on subsequent insulin initiation or dosing changes in a large cardiovascular outcomes trial…”
Get full text

Bleeding and outcome in acute coronary syndrome: Insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial by Yan, Andrew T., MD, Yan, Raymond T., MD, Huynh, Thao, MD, DeYoung, Paul, MD, Weeks, Andrew, MD, Fitchett, David H., MD, Langer, Anatoly, MD, MSc, Goodman, Shaun G., MD, MSc

“…Background Bleeding is associated with adverse outcome in acute coronary syndromes. However, the precise pathophysiologic mechanisms have not been elucidated…”
Get full text